Y-receptors control energy homeostasis, but the role of Npy6 receptors (Npy6r) is largely unknown. Young Npy6r-deficient (Npy6r −/− ) mice have reduced body weight, lean mass, and adiposity, while older and high-fat-fed Npy6r −/− mice have low lean mass with increased adiposity. Npy6r −/− mice showed reduced hypothalamic growth hormone releasing hormone (Ghrh) expression and serum insulin-like growth factor-1 (IGF-1) levels relative to WT. This is likely due to impaired vasoactive intestinal peptide (VIP) signaling in the suprachiasmatic nucleus (SCN), where we found Npy6r coexpressed in VIP neurons. Peripheral administration of pancreatic polypeptide (PP) increased Fos expression in the SCN, increased energy expenditure, and reduced food intake in WT, but not Npy6r −/− , mice. Moreover, intraperitoneal (i.p.) PP injection increased hypothalamic Ghrh mRNA expression and serum IGF-1 levels in WT, but not Npy6r −/− , mice, an effect blocked by intracerebroventricular (i.c.v.) Vasoactive Intestinal Peptide (VPAC) receptors antagonism. Thus, PP-initiated signaling through Npy6r in VIP neurons regulates the growth hormone axis and body composition.
Introduction
Hypothalamic circuitries are important in receiving and integrating information from other brain areas as well as the periphery to control appetite and energy homeostasis (Sainsbury et al., 2002a) . Among the many systems involved that influence orexigenic and anorexigenic processes in the hypothalamus, the neuropeptide Y (NPY) system is unique in that its major neuronal component, NPY, stimulates appetite and reduces energy expenditure, whereas its other family members, peptide YY (PYY) and pancreatic polypeptide (PP), which are mainly produced by endocrine cells in the periphery in response to food intake, act in an opposing fashion as satiety factors (Nguyen et al., 2011 and Zhang et al., 2011) . All three peptides are able to signal through a set of five known Y-receptors (Npy1r, Npy2r, Ppyr1, Npy5r, and Npy6r) for which they have different affinities ( Nguyen et al., 2011 and Zhang et al., 2011) . It has now been well established through work with transgenic and knockout mouse models that Npy1r and Npy5r are mostly responsible for the appetite-stimulatory and energyexpenditure-related aspects of NPY signaling in the hypothalamus ( Nguyen et al., 2012) , whereas the Npy2r and Ppyr1 are more critical for mediating satiety and other related aspects , Sainsbury et al., 2002b , Shi et al., 2010 . However, despite the large amount of work being dedicated to unraveling functions of the NPY system in the regulation of energy homeostasis, no information is available for the role of the Npy6r.
The Npy6r gene is less conserved than the other Y-receptors. It exists only as a truncated version in primate species, including humans ( Gregor et al., 1996 , Matsumoto et al., 1996 and Rose et al., 1997 , and it is absent from the rat genome (Burkhoff et al., 1998) . The human Npy6r gene is located on chromosome 5q31 ( Gregor et al., 1996) and contains a single-base deletion resulting in a frameshift mutation and an early stop codon ( Gregor et al., 1996 , Matsumoto et al., 1996 and Rose et al., 1997 . Interestingly, an alternative splice variant of the Npy1r has been discovered in the mouse leading to a truncated isoform of the protein similar to the human Npy6r ( Nakamura et al., 1995) , suggesting a potential for altered signaling capacity by Npy1r. Importantly, mRNA for the truncated Npy1r and the Npy6r is produced in considerable amounts, and in the case of the human Npy6r, mRNA is produced in the heart, skeletal muscle, gastrointestinal tissues, and adrenal glands as well as in the brain ( Burkhoff et al., 1998 , Gregor et al., 1996 and Matsumoto et al., 1996 , raising questions as to its possible function.
In contrast to humans, primates, and rats, the Npy6r gene is present in a nontruncated form in mice and rabbits ( Burkhoff et al., 1998 and Matsumoto et al., 1996) . In the mouse, Npy6r is expressed in the developing embryo, skeletal muscle, kidney, and testes ( Burkhoff et al., 1998 and Gregor et al., 1996) . More importantly, in situ hybridization confirmed Npy6r expression in the mouse hypothalamus ( Weinberg et al., 1996) , suggesting a role for this receptor in the regulation of energy homeostasis. Controversy surrounds the pharmacological profile of the Npy6r, with some studies claiming an Npy1r-like profile ( Weinberg et al., 1996) , others indicating a Ppyr1-like profile ( Gregor et al., 1996) , and a further study describing a unique pharmacological profile of Npy6r distinct from all the other Y receptors ( Mullins et al., 2000) . This lack of consistent results arising from previous in vitro studies makes it difficult to ascertain the true pharmacology and potential physiological role of Npy6r.
Considering that mice are frequently used to determine the functional role of individual Y receptors, as well as the possibility that manipulation of the NPY system could be used for the development of new therapeutics for the treatment of obesity, diabetes, and related disorders, it is important to evaluate the contribution of all Y-receptors to the regulation of energy homeostasis, including Npy6r in the mouse. Therefore, in this study we investigated the metabolic characteristics and hypothalamic circuits activated by Npy6r signaling using Npy6r knockout mice (Npy6r −/− ). To gain further insights into the critical physiological functions of Npy6r in mice, we also used our Npy6r −/− mouse model to determine the physiological ligand for this Y-receptor in vivo.
Results

Npy6r
−/− Mice Are Viable and Have Normal Fertility Npy6r gene deletion was achieved by inserting a lacZ-IRES-neoR selection cassette into the coding frame of the Npy6r gene, allowing for identification of normal sites of gene expression via X-gal staining for β-galactosidase ( Figure 1A ). Npy6r −/− mice were identified by PCR ( Figure 1B) and confirmed by RT-PCR in various tissues ( Figure 1C ). Utilizing the introduced lacZ gene, we investigated the expression pattern of Npy6r in a variety of peripheral tissues and throughout the brain (see Figures S1 and S2 online). Only a subset of neurons within the hypothalamic supracharismatic nucleus (SCN) showed staining for β-gal, with no staining in any other area of the brain or the peripheral tissues examined, except testes. This demonstrates that Npy6r signaling in the brain is restricted to the SCN.
Npy6r −/− mice are viable; however, they are smaller than their wild-type (WT) counterparts ( Figure 1D ). Breeding of heterozygous Npy6r +/− mice resulted in live offspring with a genotype frequency not different from the expected Mendelian ratio (Table S1 ). Since Npy6r are expressed in the testes, we investigated whether deletion of this receptor impacts on fertility. Homozygous Npy6r −/− breeding pairs produced litters of a similar size to litters from WT and heterozygous breeding pairs (Table S1 ). Additionally, the mortality rate and gender ratio of pups born from heterozygous and homozygous breeding pairs did not significantly differ from that of WT (Table S1) , further suggesting that disruption of Npy6r expression does not have any impact upon reproductive fitness.
Lack of Npy6r Signaling Leads to an Early Reduction in Body Weight, Reduced Lean Mass, and the Development of Late-Onset Obesity Npy6r
−/− mice showed reduced body weights relative to WT mice from 6 to 23 weeks of age but were no longer different at 24 weeks of age ( Figure 1E ). Npy6r −/− mice showed markedly reduced lean body mass when analyzed by whole-body dual-energy X-ray absorptiometry (DXA) at 9, 15, 20, and 24 weeks of age ( Figure 1F ). Importantly, lean body mass as a percent of body weight was also lower in 20-and 24-week-old Npy6r −/− mice compared to WT mice ( Figure 1G ), suggesting a disproportionate reduction in lean mass in the knockouts. Deletion of Npy6r also led to a transient reduction in absolute fat mass at 15 weeks of age ( Figure 1F ), but at 20 or 24 weeks of age, Npy6r −/− mice showed greater adiposity (Figures 1F and IG) . Consistent with the DXA scan results, the absolute or relative weights of dissected white adipose tissues depots from the inguinal (i), epididymal (e), retroperitoneal (r), and mesenteric (m) sites and the brown adipose tissue (b) were significantly reduced in the absence of Npy6r in 15-week-old mice ( Figures 1H and 1I) . In contrast to this reduction in adiposity at an early age, the weights of dissected white and brown adipose tissue depots were markedly greater in 24-week-old Npy6r −/− mice ( Figures 1J and 1K ). normalized for lean body mass ( Figure 2G ). Associated with this, Npy6r À/À mice exhibited significantly increased activity (Figure 2H) . We further inquired if changes in resting metabolic rate could also contribute to the observed increase in energy expenditure in Npy6r À/À mice by analyzing the energy expenditure corresponding to the hour of least activity and found no significant difference (Figures S4A and S4B; Table S2 ). In addition, we assessed resting metabolic rate by extrapolating regression lines of energy expenditure to physical activity and found that resting energy expenditure is not significantly different between 14-week-old Npy6r À/À and WT mice (Figures S4A and S4B; Table S2 ). These results indicate that the absence of Npy6r signaling does not increase basal metabolic rate, and that the increase in energy expenditure observed in 14-week-old Npy6r À/À mice was most likely due to the increase in physical activity. In addition to increased energy expenditure, 14-week-old Npy6r À/À mice demonstrated a significant elevation in respiratory exchange ratio (RER), indicative of a reduction in lipid utilization for whole-body energy production ( Figure 2I ). While the elevated RER in Npy6r À/À mice may reflect the reduced adiposity in 15-week-old Npy6r À/À mice ( Figures 1F and 1H) , an RER value greater than 1.0, as seen in Npy6r À/À mice between 22:00 and 02:00 hr ( Figure 2I ), is associated with de novo lipogenesis (Schutz, 2004) . Since an increase in RER has been demonstrated to predict weight gain (Marra et al., 2004; Seidell et al., 1992; Weinsier et al., 1995) , these data are in line with the development of a late-onset increase in adiposity in Npy6r À/À mice.
Secondary to the age-induced increase in adiposity, 23-weekold Npy6r À/À mice displayed a significant reduction in RER (Figure 2J) , suggesting an increased preference for lipids as an oxidative fuel source. Consistent with the increased energy expenditure and physical activity seen in 14-week-old Npy6r À/À mice, 23-week-old Npy6r À/À showed significant increases in energy expenditure when normalized for lean mass (Figures 2K and 2L) , as well as an increase in physical activity during the light phase ( Figure 2M ). Furthermore, resting energy expenditure was significantly higher in Npy6r À/À mice at 23 weeks of age (Figures  S4C and S4D; Table S2 ). These data suggest that, in addition to increased physical activity, an increase in basal metabolic rate is an important contributor to the increased total energy expenditure observed in 23-week-old Npy6r À/À mice.
Npy6r Signaling Is Critical for Maintaining Glucose Homeostasis in Mice Skeletal muscle is a major site of insulin-mediated glucose disposal, and a reduction in lean mass is associated with impairment in glucose homeostasis and insulin sensitivity (Dulloo, 2009 ). Since Npy6r À/À mice demonstrated a significant reduction in lean body mass, we suspected that glucose metabolism might be impaired in these mice. Interestingly, 15-week-old Npy6r À/À mice exhibited normoglycemia under fasted and nonfasted conditions ( Figure 3A ). Despite this, Npy6r À/À mice at 15 weeks of age exhibited reduced serum insulin concentrations, significantly so in the nonfasted condition ( Figure 3B ), suggesting improved insulin action on glucose clearance. Indeed, in response to i.p. glucose administration, the area under the curve for the glucose tolerance tests were significantly reduced in 15-week-old Npy6r À/À mice (Figures 3C and 3D) despite significantly lower serum insulin concentrations ( Figure 3E ).
In contrast, while fasted and nonfasted blood glucose levels were similar between 24-week-old Npy6r À/À and WT mice (Figure 3F) , the heightened fat accumulation in Npy6r À/À mice of this age is accompanied by a significant elevation in nonfasting serum insulin concentrations ( Figure 3G ), suggesting decreased insulin action in older Npy6r À/À mice. Consistent with this, we found that insulin signaling in muscle and liver, as determined by Akt phosphorylation, is reduced in 24-week-old Npy6r À/À mice (Figures S5A and S5B) . Despite this, Npy6r deficiency did not result in deterioration in glucose tolerance, with blood glucose and serum insulin levels in response to i.p. glucose injection being similar between 24-week-old Npy6r À/À and WT mice ( Figures 3H and 3I ).
Npy6r -/-Mice Show Exacerbated Diet-Induced Obesity
We next assessed the effect of Npy6r deletion in mice on a highfat diet (HFD), which was introduced at 7 weeks of age and continued for 16 weeks. Relative to WT, Npy6r À/À mice exhibited significantly lower starting body weights ( Figure 4A ) but displayed significantly greater relative body weight gain on the HFD ( Figure 4B ). Importantly, after 8 weeks on the HFD (i.e., 15 weeks of age) Npy6r À/À mice showed similar body weights to age-matched WT controls ( Figure 4A) , showing that the normalization of body weight in 24-week-old chow-fed Npy6r À/À mice seen in Figure 1E was accelerated by the obesogenic diet.
Consistent with the effect of Npy6r deletion in mice on a normal chow diet ( Figures 1F and 1G ), HFD-fed Npy6r À/À mice displayed reduced lean body mass as determined by wholebody DXA scans and when expressed as either absolute weight or as a percent of body weight ( Figures 4C and 4D ). Npy6r À/À mice also showed significantly higher adiposity at 7 and 14 weeks after the commencement of HFD feeding (Figures 4C and 4D) . This greater adiposity was confirmed by significantly greater absolute and relative masses of dissected white and brown adipose tissue depots in Npy6r À/À mice after 16 weeks on the HFD ( Figures 4E and 4F ). These data show that, together with the suppression of lean body mass, the impact of Npy6r (C) Npy6r mRNA expression was determined in various tissues, including the hypothalamus, testes, and inguinal white adipose tissue (i), by RT-PCR using GAPDH as a housekeeping gene. (D) A representative photograph of 15-week-old WT and Npy6r À/À mice. (E) Body weight in Npy6r À/À and WT mice was measured on a weekly basis. (F and G) Body composition (lean and fat mass) was determined by DXA and normalized to body weight at indicated time points in Npy6r À/À and WT mice. (H-K) Absolute and relative (as a percent of body weight) weights of white adipose tissues from the inguinal (i), epidydimal (e), mesenteric (m), and retroperitoneal (r) sites, and intrascapular brown adipose tissue (b) depots were measured in 15-and 24-week-old Npy6r À/À and WT mice. (L-N) (L) Liver weight and (M and N) liver morphology were determined by the quantity of oil red O staining from 15-and 24-week-old Npy6r À/À and WT mice. (O and P) Representative oil red O-stained liver sections from WT and Npy6r À/À mice. Data are means ±SEM of 5-13 mice per group. See also Figures S1 and S2 and Table S1.
Cell Metabolism
PP Controls Energy Homeostasis
Cell Metabolism 19, 58-72, January 7, 2014 Since obesity is associated with ectopic lipid deposition in various tissues including the liver, we investigated this in our Npy6r −/− mice. Interestingly, we found a significant increase in liver weight relative to body weight in Npy6r −/− mice at 15 weeks of age ( Figure 1L ). This was associated with a significantly greater amount of lipid in the livers of these mice ( Figure 1M ), as determined by oil red O staining ( Figure 1O ). Consistent with this, 24-week-old Npy6r −/− mice also exhibited significantly higher hepatic lipid accumulation ( Figures 1N and 1P ). Since Npy6r −/− mice showed reduced adiposity at 15 weeks of age ( Figures 1F, 1H , and 1I), this result suggests that ectopic fat accumulation in the liver precedes the development of age-induced fat accumulation in Npy6r −/− mice.
Reduced Body Weight and Preferential Fat Accumulation in Npy6r −/− Mice Are Associated with Increased Cumulative Food Intake Relative to Body Weight To determine if the reduction in body weight and altered body composition in Npy6r −/− mice could be explained by changes in feeding behavior, we analyzed the food intake of Npy6r −/− and WT mice. Spontaneous food intake and spillage did not differ significantly between genotypes at 15 weeks of age ( Figure 2A ). However, Npy6r −/− mice exhibited a trend toward increased daily food intake at 24 weeks of age ( Figure 2B ). In spite of this, Npy6r −/− mice displayed significantly greater fecal output at 15, but not at 24, weeks of age (Figures S3A and S3B) . Following a 24 hr fast at 13 weeks of age, food intake, spillage ( Figure 2C ), and fecal output ( Figure S3C ) were similar between Npy6r −/− and WT mice. Since food spillage was not significantly different between Npy6r −/− and WT mice, we also monitored food intake as the amount of food removed from the hopper over the entire period between 16 and 22 weeks of age and found no significant difference in cumulative food consumption ( Figure 2D ). Importantly, however, these differences were statistically significant when normalized for body weight (Figure 2E ), indicating that increased food intake may contribute to the increased adiposity and weight gain in older Npy6r −/− mice. Indirect calorimetry on 14-week-old Npy6r −/− mice revealed a significant increase in energy expenditure compared to WT, either when expressed as absolute values ( Figure 2F ) or when normalized for lean body mass ( Figure 2G ). Associated with this, Npy6r −/− mice exhibited significantly increased activity ( Figure 2H ). We further inquired if changes in resting metabolic rate could also contribute to the observed increase in energy expenditure in Npy6r −/− mice by analyzing the energy expenditure corresponding to the hour of least activity and found no significant difference (Figures S4A and S4B; Table S2 ). In addition, we assessed resting metabolic rate by extrapolating regression lines of energy expenditure to physical activity and found that resting energy expenditure is not significantly different between 14-week-old Npy6r −/− and WT mice (Figures S4A and S4B; Table S2 ). These results indicate that the absence of Npy6r signaling does not increase basal metabolic rate, and that the increase in energy expenditure observed in 14-week-old Npy6r −/− mice was most likely due to the increase in physical activity.
In addition to increased energy expenditure, 14-week-old Npy6r −/− mice demonstrated a significant elevation in respiratory exchange ratio (RER), indicative of a reduction in lipid utilization for whole-body energy production ( Figure 2I ). While the elevated RER in Npy6r −/− mice may reflect the reduced adiposity in 15-week-old Npy6r −/− mice ( Figures 1F and 1H ), an RER value greater than 1.0, as seen in Npy6r −/− mice between 22:00 and 02:00 hr ( Figure 2I ), is associated with de novo lipogenesis (Schutz, 2004) . Since an increase in RER has been demonstrated to predict weight gain ( Marra et al., 2004 , Seidell et al., 1992 and Weinsier et al., 1995 , these data are in line with the development of a late-onset increase in adiposity in Npy6r −/− mice. Secondary to the age-induced increase in adiposity, 23-week-old Npy6r −/− mice displayed a significant reduction in RER ( Figure 2J ), suggesting an increased preference for lipids as an oxidative fuel source. Consistent with the increased energy expenditure and physical activity seen in 14-week-old Npy6r −/− mice, 23-week-old Npy6r −/− showed significant increases in energy expenditure when normalized for lean mass ( Figures 2K and 2L ), as well as an increase in physical activity during the light phase ( Figure 2M ). Furthermore, resting energy expenditure was significantly higher in Npy6r −/− mice at 23 weeks of age (Figures S4C  and S4D; Table S2 ). These data suggest that, in addition to increased physical activity, an increase in basal metabolic rate is an important contributor to the increased total energy expenditure observed in 23-week-old Npy6r −/− mice. deficiency in enhancing adiposity in mice is exacerbated by the HFD. Interestingly, the exacerbated body weight gain and adipose tissue accumulation in Npy6r À/À mice on a HFD occurred in the presence of transient hyperphagia. While food intake in absolute weight did not differ significantly between genotypes at 3 weeks after the introduction of HFD ( Figure 4G ), Npy6r À/À mice consumed significantly more HFD relative to their body weights compared to WT controls at this time point ( Figure 4H ). In contrast, food intake of Npy6r À/À mice was significantly reduced after 13 weeks on the HFD (Figures 4G and 4H ). Reflec-tive of the changes in absolute food consumption ( Figure 4G ), fecal output was significantly reduced after 10 but not 3 weeks of high-fat feeding in Npy6r À/À mice ( Figure S3D ). In response to a 24 hr fast, young Npy6r À/À mice exhibited no change in food intake (Figures 4I and 4J) or fecal output ( Figure S3E ), whereas older knockouts demonstrated a significant reduction in fasting-induced food intake (Figures 4K and 4L) and fecal output ( Figure S3F ). The transient increase in nonfasted food intake relative to body weight seen at 3 weeks after the provision of HFD ( Figure 4H ) may contribute to the accelerated body weight gain in HFD-fed Npy6r À/À mice. Additionally, since (A-C) Daily and 24 hr fasting-induced food intake and spillage were assessed in Npy6r À/À and WT mice at indicated time points. (D and E) Cumulative food consumption from 16-to 22-week-old Npy6r À/À and WT mice were recorded and normalized to total body weight. (F-M) Light and dark cycle energy expenditure (normalized to total lean mass), ambulatory activity, and respiratory exchange ratio (RER) were determined in metabolic chambers during indirect calorimetry studies in 14-and 23-week-old Npy6r À/À and WT mice. Significant time and genotype interaction effects are indicated by J. Npy6r Signaling Is Critical for Maintaining Glucose Homeostasis in Mice Skeletal muscle is a major site of insulin-mediated glucose disposal, and a reduction in lean mass is associated with impairment in glucose homeostasis and insulin sensitivity (Dulloo, 2009 ). Since Npy6r −/− mice demonstrated a significant reduction in lean body mass, we suspected that glucose metabolism might be impaired in these mice. Interestingly, 15-weekold Npy6r −/− mice exhibited normoglycemia under fasted and nonfasted conditions ( Figure 3A ). Despite this, Npy6r −/− mice at 15 weeks of age exhibited reduced serum insulin concentrations, significantly so in the nonfasted condition ( Figure 3B ), suggesting improved insulin action on glucose clearance. Indeed, in response to i.p. glucose administration, the area under the curve for the glucose tolerance tests were significantly reduced in 15-week-old Npy6r −/− mice ( Figures 3C and 3D ) despite significantly lower serum insulin concentrations ( Figure 3E ).
In contrast, while fasted and nonfasted blood glucose levels were similar between 24week-old Npy6r −/− and WT mice ( Figure 3F ), the heightened fat accumulation in Npy6r −/− mice of this age is accompanied by a significant elevation in nonfasting serum insulin concentrations ( Figure 3G ), suggesting decreased insulin action in older Npy6r −/− mice. Consistent with this, we found that insulin signaling in muscle and liver, as determined by Akt phosphorylation, is reduced in 24-week-old Npy6r −/− mice ( Figures S5A and S5B ). Despite this, Npy6r deficiency did not result in deterioration in glucose tolerance, with blood glucose and serum insulin levels in response to i.p. glucose injection being similar between 24-weekold Npy6r −/− and WT mice ( Figures 3H and 3I ).
deficiency in enhancing adiposity in mice is exacerbated by the HFD. Interestingly, the exacerbated body weight gain and adipose tissue accumulation in Npy6r À/À mice on a HFD occurred in the presence of transient hyperphagia. While food intake in absolute weight did not differ significantly between genotypes at 3 weeks after the introduction of HFD ( Figure 4G ), Npy6r À/À mice consumed significantly more HFD relative to their body weights compared to WT controls at this time point ( Figure 4H ). In contrast, food intake of Npy6r À/À mice was significantly reduced after 13 weeks on the HFD (Figures 4G and 4H ). Reflec-tive of the changes in absolute food consumption ( Figure 4G ), fecal output was significantly reduced after 10 but not 3 weeks of high-fat feeding in Npy6r À/À mice ( Figure S3D ). In response to a 24 hr fast, young Npy6r À/À mice exhibited no change in food intake (Figures 4I and 4J) or fecal output ( Figure S3E ), whereas older knockouts demonstrated a significant reduction in fasting-induced food intake ( Figures 4K and 4L ) and fecal output ( Figure S3F ). The transient increase in nonfasted food intake relative to body weight seen at 3 weeks after the provision of HFD ( Figure 4H ) may contribute to the accelerated body weight gain in HFD-fed Npy6r À/À mice. Additionally, since (A-C) Daily and 24 hr fasting-induced food intake and spillage were assessed in Npy6r À/À and WT mice at indicated time points. (D and E) Cumulative food consumption from 16-to 22-week-old Npy6r À/À and WT mice were recorded and normalized to total body weight. (F-M) Light and dark cycle energy expenditure (normalized to total lean mass), ambulatory activity, and respiratory exchange ratio (RER) were determined in metabolic chambers during indirect calorimetry studies in 14-and 23-week-old Npy6r À/À and WT mice. Significant time and genotype interaction effects are indicated by J. Data are means ±SEM of five to nine mice per group. See also Figures S3 and S4 and Table S2 . Npy6r −/− Mice Show Exacerbated Diet-Induced Obesity We next assessed the effect of Npy6r deletion in mice on a high-fat diet (HFD), which was introduced at 7 weeks of age and continued for 16 weeks. Relative to WT, Npy6r −/− mice exhibited significantly lower starting body weights ( Figure 4A ) but displayed significantly greater relative body weight gain on the HFD ( Figure 4B ). Importantly, after 8 weeks on the HFD (i.e., 15 weeks of age) Npy6r −/− mice showed similar body weights to age-matched WT controls ( Figure 4A) , showing that the normalization of body weight in 24-week-old chow-fed Npy6r −/− mice seen in Figure 1E was accelerated by the obesogenic diet. nonfasted and fasting-induced food intake at the later time point were significantly reduced, lack of Npy6r in mice may lead to increased feeding efficacy and greater body weight gain seen in HFD-fed Npy6r À/À mice.
Using indirect calorimetry we identified that after 14 weeks on the HFD, Npy6r À/À mice did not exhibit any difference in absolute energy expenditure ( Figure 4M ). When adjusted for the difference in lean body mass, however, energy expenditure was significantly greater in HFD-fed Npy6r À/À mice ( Figure 4N ). This increase in energy expenditure was more pronounced than that seen in chow-fed Npy6r À/À mice at either the younger age or the older age ( Figures 2G and 2L ). Unlike in chow-fed animals ( Figure 2H -2J and 2M), we did not detect any significant differences in physical activity ( Figure 4O ) or RER ( Figure 4P ) between HFD-fed Npy6r À/À and WT mice. These results show that the increase in body weight gain and fat accumulation in Npy6r À/À mice on the HFD is not due to reduced metabolism.
Interestingly, after 12 weeks on the HFD, Npy6r À/À mice still displayed normoglycemia ( Figure 4Q ) but showed elevated serum insulin levels, significantly so in the nonfasted state (Figure 4R) . However, when assessed for glucose tolerance, Npy6r À/À mice on HFD displayed markedly higher blood glucose ( Figure 4S ) and serum insulin levels ( Figure 4T ) in response to i.p. glucose injection, signifying impaired glucose metabolism. Taken together, our data demonstrate that deficiency in Npy6r in mice exacerbates diet-induced obesity and promotes the associated abnormalities in glucose homeostasis.
Npy6r -/-Mice Have Impaired Central VIP Signaling in Association with Reduced Serum IGF-1 and Blunted Corticosterone Rhythm In order to identify the underlying mechanism that leads to the altered metabolic phenotype of Npy6r deficiency, we focused on areas of highest Npy6r expression. As shown in Figures 5A, S1, and S2, the strongest expression of Npy6r was found in the hypothalamic SCN, with expression also detected in the testes. It is known that reduction in circulating testosterone levels is strongly linked to reduced lean body mass (Sattler et al., 2009 ) and obesity (Nettleship et al., 2007) . However, Npy6r À/À mice did not show reduced serum testosterone levels ( Figure S6A ), suggesting that this is not a major contributor to the observed phenotype.
In order to elucidate possible pathways by which Npy6r signaling may regulate energy balance and body composition, we determined the molecular identity of Npy6r-expressing neurons in the SCN by utilizing the introduced lacZ gene into the Npy6r gene coding region to visualize the expression pattern of Npy6r by staining for b-gal. Immunostaining with antibodies against a variety of neuropeptides known to be expressed in the SCN (Reghunandanan et al., 1993) revealed vasoactive intestinal peptide (VIP) as colocalized with the Npy6r (Figures  S6B and S6C ). To further confirm this colocalization, we performed in situ hybridization for Vip mRNA on SCN sections previously stained for LacZ. As shown in Figures 5B and 5C , almost all LacZ-positive neurons express VIP, shown in the overlaying silver grains. In contrast, immunostaining using arginine vasopressin (AVP) antibody did not show any overlap in expression with Npy6r-positive neurons (Figures 5D and 5E ).
PP Is the Endogenous High-Affinity Ligand for the Npy6r in Mice
The SCN receives input from a variety of areas in the brain (Welsh et al., 2010) . Additionally, the SCN is accessible to factors derived from the circulation (Welsh et al., 2010) , including peripherally derived PP and PYY. To investigate which Y-receptor ligand is the most effective transducer of Npy6r function in vivo, (M-P) After 12 weeks of high-fat feeding, energy expenditure, ambulatory activity, and respiratory exchange ratio (RER) were determined. (Q and R) Fasted and nonfasted blood glucose and serum insulin levels were determined. (S and T) Mice were fasted for 6 hr and injected with glucose (1 mg/kg). Blood glucose and corresponding insulin levels at indicated time points were assessed. Data are means ±SEM of nine males per group. See also Figure S3 . Consistent with the effect of Npy6r deletion in mice on a normal chow diet ( Figures  1F and 1G) , HFD-fed Npy6r −/− mice displayed reduced lean body mass as determined by whole-body DXA scans and when expressed as either absolute weight or as a percent of body weight (Figures 4C and 4D ). Npy6r −/− mice also showed significantly higher adiposity at 7 and 14 weeks after the commencement of HFD feeding ( Figures 4C and 4D ). This greater adiposity was confirmed by significantly greater absolute and relative masses of dissected white and brown adipose tissue depots in Npy6r −/− mice after 16 weeks on the HFD ( Figures  4E and 4F) . These data show that, together with the suppression of lean body mass, the impact of Npy6r deficiency in enhancing adiposity in mice is exacerbated by the HFD.
Interestingly, the exacerbated body weight gain and adipose tissue accumulation in Npy6r −/− mice on a HFD occurred in the presence of transient hyperphagia. While food intake in absolute weight did not differ significantly between genotypes at 3 weeks after the introduction of HFD ( Figure 4G ), Npy6r −/− mice consumed significantly more HFD relative to their body weights compared to WT controls at this time point ( Figure 4H ). In contrast, food intake of Npy6r −/− mice was significantly reduced after 13 weeks on the HFD (Figures 4G and  4H) . Reflective of the changes in absolute food consumption ( Figure 4G ), fecal output was significantly reduced after 10 but not 3 weeks of high-fat feeding in Npy6r −/− mice ( Figure S3D) . In response to a 24 hr fast, young Npy6r −/− mice exhibited no change in food intake (Figures 4I and 4J) or fecal output ( Figure S3E ), whereas older knockouts demonstrated a significant reduction in fasting-induced food intake ( Figures 4K and 4L ) and fecal output ( Figure S3F ). The transient increase in nonfasted food intake relative to body weight seen at 3 weeks after the provision of HFD ( Figure 4H ) may contribute to the accelerated body weight gain in HFD-fed Npy6r −/− mice. Additionally, since nonfasted and fasting-induced food intake at the later time point were significantly reduced, lack of Npy6r in mice may lead to increased feeding efficacy and greater body weight gain seen in HFD-fed Npy6r −/− mice.
Using indirect calorimetry we identified that after 14 weeks on the HFD, Npy6r −/− mice did not exhibit any difference in absolute energy expenditure ( Figure 4M ). When adjusted for the difference in lean body mass, however, energy expenditure was significantly greater in HFD-fed Npy6r −/− mice ( Figure 4N ). This increase in energy expenditure was more pronounced than that seen in chow-fed Npy6r −/− mice at either the younger age or the older age ( Figures 2G and 2L) . Unlike in chow-fed animals ( Figure 2H -2J and 2M), we did not detect any significant differences in physical activity ( Figure 4O ) or RER ( Figure 4P ) between HFD-fed Npy6r −/− and WT mice. These results show that the increase in body weight gain and fat accumulation in Npy6r −/− mice on the HFD is not due to reduced metabolism. Interestingly, after 12 weeks on the HFD, Npy6r −/− mice still displayed normoglycemia ( Figure 4Q ) but showed elevated serum insulin levels, significantly so in the nonfasted state ( Figure 4R ). However, when assessed for glucose tolerance, Npy6r −/− mice on HFD displayed markedly higher blood glucose ( Figure 4S ) and serum insulin levels ( Figure 4T ) in response to i.p. glucose injection, signifying impaired glucose metabolism. Taken together, our data demonstrate that deficiency in Npy6r in mice exacerbates diet-induced obesity and promotes the associated abnormalities in glucose homeostasis.
Npy6r −/− Mice Have Impaired Central VIP Signaling in Association with Reduced Serum IGF-1 and Blunted Corticosterone Rhythm
In order to identify the underlying mechanism that leads to the altered metabolic phenotype of Npy6r deficiency, we focused on areas of highest Npy6r expression. As shown in Figures 5A, S1, and S2, the strongest expression of Npy6r was found in the hypothalamic SCN, with expression also detected in the testes. It is known that reduction in circulating testosterone levels is strongly linked to reduced lean body mass ( Sattler et al., 2009 ) and obesity (Nettleship et al., 2007) . However, Npy6r −/− mice did not show reduced serum testosterone levels ( Figure S6A ), suggesting that this is not a major contributor to the observed phenotype.
In order to elucidate possible pathways by which Npy6r signaling may regulate energy balance and body composition, we determined the molecular identity of Npy6rexpressing neurons in the SCN by utilizing the introduced lacZ gene into the Npy6r gene coding region to visualize the expression pattern of Npy6r by staining for β-gal. Immunostaining with antibodies against a variety of neuropeptides known to be expressed in the SCN ( Reghunandanan et al., 1993) revealed vasoactive intestinal peptide (VIP) as colocalized with the Npy6r ( Figures S6B and S6C) . To further confirm this colocalization, we performed in situ hybridization for Vip mRNA on SCN sections previously stained for LacZ. As
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shown in Figures 5B and 5C , almost all LacZ-positive neurons express VIP, shown in the overlaying silver grains. In contrast, immunostaining using arginine vasopressin (AVP) antibody did not show any overlap in expression with Npy6r-positive neurons ( Figures 5D  and 5E ).
PP Is the Endogenous High-Affinity Ligand for the Npy6r in Mice
The SCN receives input from a variety of areas in the brain (Welsh et al., 2010) . Additionally, the SCN is accessible to factors derived from the circulation (Welsh et al., 2010) , including peripherally derived PP and PYY. To investigate which Y-receptor ligand is the most effective transducer of Npy6r function in vivo, we examined the expression of Fos in the SCN of Npy6r −/− and WT mice in response to i.p. administration of either PP, PYY, PYY3-36, or saline. Injection of PYY or PYY3-36 into WT mice did not induce any significant differences in Fos expression in the SCN compared to saline controls ( Figure 6A ) but significantly increased Fos expression in other areas like the arcuate nucleus (ARC) (data not shown). Importantly, a significant increase in Fos immunoreactivity in the SCN of WT mice was seen following i.p. PP injection, and this effect was absent in Npy6r −/− mice ( Figures 6A and 6B ). To further nonfasted and fasting-induced food intake at the later time point were significantly reduced, lack of Npy6r in mice may lead to increased feeding efficacy and greater body weight gain seen in HFD-fed Npy6r À/À mice.
Using indirect calorimetry we identified that after 14 weeks on the HFD, Npy6r À/À mice did not exhibit any difference in absolute energy expenditure ( Figure 4M ). When adjusted for the difference in lean body mass, however, energy expenditure was significantly greater in HFD-fed Npy6r À/À mice ( Figure 4N ). This increase in energy expenditure was more pronounced than that seen in chow-fed Npy6r À/À mice at either the younger age or the older age ( Figures 2G and 2L) . Unlike in chow-fed animals ( Figure 2H -2J and 2M), we did not detect a ences in physical activity ( Figure 4O ) or RER HFD-fed Npy6r À/À and WT mice. These re increase in body weight gain and fat accum mice on the HFD is not due to reduced me Interestingly, after 12 weeks on the HFD displayed normoglycemia ( Figure 4Q ) bu serum insulin levels, significantly so in the ure 4R). However, when assessed for Npy6r À/À mice on HFD displayed markedly ( Figure 4S ) and serum insulin levels (Figure 4 glucose injection, signifying impaired g Taken together, our data demonstrate that in mice exacerbates diet-induced obesity associated abnormalities in glucose homeo
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In order to elucidate possible pathwa signaling may regulate energy balance and we determined the molecular identity of Np rons in the SCN by utilizing the introduce Npy6r gene coding region to visualize the of Npy6r by staining for b-gal. Immunostai against a variety of neuropeptides known the SCN (Reghunandanan et al., 1993) rev testinal peptide (VIP) as colocalized with S6B and S6C). To further confirm this co formed in situ hybridization for Vip mRNA o viously stained for LacZ. As shown in Figure  all , 2010) . Additionally, the SCN is a derived from the circulation (Welsh et al., 20 erally derived PP and PYY. To investiga ligand is the most effective transducer of N (M-P) After 12 weeks of high-fat feeding, energy expenditure, ambulatory activity, and respiratory exchange ratio (RER) were determ (Q and R) Fasted and nonfasted blood glucose and serum insulin levels were determined. (S and T) Mice were fasted for 6 hr and injected with glucose (1 mg/kg). Blood glucose and corresponding insulin levels at indicated tim Data are means ±SEM of nine males per group. See also Figure S3 . et al.: Cell Metabolism, 19(1): 58--72, 2012 confirm this, we performed radioligand-binding assays on brain sections from WT and Npy6r −/− mice using I 125 -labeled PP. Supporting the notion that PP is a physiological activator of Npy6r, I 125 -labeled PP binding was detected in the SCN of WT mice, but not in Npy6r −/− brain sections ( Figure S7A ). By contrast, the binding of I 125 -labeled PP was not observed in WT brain slices cotreated with human PP (Figure S7A ). This raises the possibility that increases in circulating PP levels due to food intake or hypoglycemia can trigger Npy6rmediated events in the SCN. Fos expression in the suprachiasmatic nucleus (SCN) of the hypothalamus was assessed by immunohistochemistry after 30 min injection. Fos-positive neurons in SCN brain sections were quantified. (C) WT and Npy6r À/À mice were injected with either saline or PP, and PFA perfused brains were extracted and processed for immunohistochemistry with antibodies to p-ERK. (D and E) WT and Npy6r À/À mice were injected with either saline or PP (300 mg/kg) as indicated, and oxygen consumption and energy expenditure were monitored by indirect calorimetry. (F and G) WT and Npy6r À/À mice were fasted for 24 hr, and prior to food being given mice were injected with either saline or PP (300 mg/kg) as indicated. Fasting-induced food intake was determined for a period of 24 hr. Data are means ±SEM of three to six mice per group. See also Figure S7 .
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Cell Metabolism 19, 58-72, January 7, 2014 Previous studies have shown that extracellular signal-related kinase (ERK) is involved in mediating downstream signaling of Y receptors, including the Npy1r ( Shi et al., 2013) . To investigate whether ERK may also act as a downstream substrate for the Npy6r in response to PP, we injected WT and Npy6r −/− mice with either saline or PP and assessed ERK phosphorylation (p-ERK) by immunohistochemistry. While PP-induced p-ERK in the SCN region was elevated in WT mice compared to saline-injected controls, induction of pERK was strongly reduced in the SCN of Npy6r −/− mice in response to PP ( Figure 6C ). Taken together, these results are in keeping with the notion that PP is a physiological ligand for Npy6r and that ERK is an important downstream substrate for Npy6r signaling.
Strong evidence exists that PP regulates energy homeostasis by decreasing food intake and increasing energy expenditure via action on Ppyr1 . Our findings that PP also activates the Npy6r raised the possibility that PP could regulate energy balance and appetite separately via an Npy6r signaling pathway. To examine this directly, both WT and Npy6r −/− mice were given an i.p. injection of saline or PP at 7 a.m. and 7 p.m., with subsequent monitoring of oxygen consumption, energy expenditure, and fasting-induced food intake. Consistent with previous studies, we found that oxygen consumption and energy expenditure were significantly increased in WT mice in response to PP injection ( Figures 6D  and 6E ). However, these differences were not noted in Npy6r −/− mice ( Figures 6D and 6E) , indicating that Npy6r is required to mediate the effects of PP in the regulation of energy expenditure. In response to PP, both WT and Npy6r −/− mice exhibited reductions in fastinginduced food intake compared to the corresponding saline group, significantly so in WT animals ( Figures 6F and 6G) . However, the degree to which PP suppressed food intake was significantly less in Npy6r −/− mice at an early time point (0-4 hr), and these differences were even greater when normalized for body weight (Figures 6F and 6G) .
PP-Mediated Npy6r Signaling Controls Vip Expression in the SCN
Having established that Npy6r are coexpressed with VIP in neurons of the SCN, we hypothesized that the metabolic phenotype of Npy6r −/− mice may be explained by impairment in downstream actions of VIP. We determined Vip mRNA levels in the hypothalamus of WT and Npy6r −/− mice by quantitative real-time PCR. Consistent with our hypothesis of impaired VIP signaling, we found that Vip expression was significantly reduced in the hypothalamus of Npy6r −/− ( Figure 7A ), but not in other peripheral tissues such as colon, small intestine, or pancreas ( Figure S7B ). Lack of change in peripheral Vip mRNA levels is consistent with unaltered serum VIP levels in Npy6r −/− mice ( Figure S7C ). Additionally, Vip expression levels in the SCN of Npy6r −/− were significantly reduced as determined by in situ hybridization ( Figures 7B and 7C) , confirming that VIP signaling is disrupted in the SCN of Npy6r −/− mice. VIP is known as a key regulator of the growth hormone (GH) axis (Asnicar et al., 2002 and Niewiadomski et al., 2008) , circadian rhythm (Aton et al., 2005 , Brown et al., 2007 , Pantazopoulos et al., 2010 and Piggins and Cutler, 2003 , and glucocorticoid secretion (Loh et al., 2008) . Previous studies showed that VIP-deficient mice exhibit reduced IGF-1 levels (Asnicar et al., 2002 and Niewiadomski et al., 2008) , and perturbation in the GH/IGF-1 axis is associated with dwarfism and increased adiposity in rodents and humans (Lichanska and Waters, 2008) . We thus hypothesized that the GH/IGF-1 axis is perturbed in Npy6r −/− mice and that this contributes to the development of reduced lean mass and late-onset obesity. Indeed, Npy6r −/− mice showed significantly reduced serum IGF-1 levels ( Figure 7D ), coinciding with a reduction in hypothalamic expression of growth hormone releasing hormone (Ghrh) ( Figure 7E ). Additionally, loss of Npy6r in mice led to blunted diurnal variations in serum corticosterone levels ( Figure 7F) . Importantly, the damped corticosterone rhythm seen in Npy6r −/− mice is not due to impaired secretion, since a 24 hr fast elicited comparable increases in corticosterone levels in mice of both genotypes, although Npy6r −/− mice showed significantly reduced corticosterone levels compared to WT controls under both fed and fasted conditions ( Figure 7G ). Since timing of food intake is linked to corticosterone secretion (Sheward et al., 2007) and has been shown to be abrogated in mice with disrupted VIP signaling (Bechtold et al., 2008) , we investigated food consumption during light and dark phases and found significantly reduced daytime feeding in Npy6r −/− mice ( Figures 7H and 7I ). Hence, our data provide evidence that the reduced lean mass and late-onset or diet-induced increases in adiposity in mice lacking Npy6r may result from reduced hypothalamic Ghrh expression and circulating IGF-1 levels, potentially attributable to impairment in VIP signaling in the SCN. Finally, to demonstrate that alterations in downstream VIP signaling are linked to the observed changes in energy homeostasis such as the reduction of IGF-1 levels, we delivered VIP(6-28), a VPAC receptors antagonist, via the i.c.v. route to WT and Npy6r À/À mice, followed 5 min later by i.p. administration of PP. Analysis of serum samples collected 30 min following PP injection revealed that blockade of VPAC receptors in WT mice completely prevented the PP-induced increase in serum IGF-1 in WT mice ( Figure 7L) . Furthermore, the effect of PP to raise serum IGF-1 was totally absent in Npy6r À/À mice ( Figure 7L) , clearly demonstrating involvement of Npy6r signaling via VIP in controlling the growth hormone axis.
DISCUSSION
In this study, we demonstrate that Npy6r signaling in the SCN is critical in the regulation of energy homeostasis. Our results show that body weight, body composition, metabolic rate, and activity of the hypothalamo-pituitary-somatotrophic axis are significantly influenced by Npy6r signaling in mice, since lack of Npy6r leads to reduced lean mass and increased energy expenditure that are accompanied by significant improvements in glucose homeostasis and reduced hypothalamic Ghrh mRNA expression and circulating IGF-1 levels. Interestingly, Npy6rdeficient mice develop late-onset obesity, and this is further exacerbated when mice are fed a high-fat diet. Additionally, we demonstrate that PP is an endogenous high-affinity ligand for Npy6r in mice, since exogenous administration of PP, but not PYY or PYY3-36, activated Npy6r-expressing neurons in the SCN, and this effect was absent in Npy6r-deficient mice. The mechanism by which Npy6r mediates its effects on the GH axis and energy homeostasis is most likely through alterations in VIP signaling in the hypothalamus. This is demonstrated by the strong overlap in expression of Vip and Npy6r within the SCN, the brain region to which the Npy6r is confined, and the significant reduction in Vip expression in this nucleus in the absence of Npy6r signaling. Moreover, the fact that i.p. PP injection increases energy expenditure and decreases food intake, hypothalamic Ghrh mRNA expression, and circulating IGF-1 levels in WT but not in Npy6r À/À mice, and that the effect on IGF-1 is blocked by prior administration of a VPAC receptors antagonist, strongly supports this stand.
It has been documented that the SCN contains the master circadian clock in mammals; it generates distinct temporal changes in biological processes such as core body temperature and hormone secretion (Huang et al., 2011) . Disruptions in circadian rhythm, whether by genetic or environmental influences, can result in metabolic dysfunction (Huang et al., 2011) . For instance, mutation of either of two key regulators of the circadian cycle, circadian locomotor output cycles kaput (CLOCK) or brain and muscle aryl hydrocarbon receptor nuclear translocator (ARNT)-like 1 (BMAL1), not only disrupt normal circadian rhythm, manifesting in loss of normal daily hormonal and feeding patterns, but also predispose mice to metabolic diseases (Marcheva et al., 2010; Rudic et al., 2004; Turek et al., 2005) . VIP is a critical regulator of circadian rhythm in the SCN, with deletion of VIP or its receptor, VPAC2, leading to loss of circadian rhythmicity and synchrony in SCN neurons (Aton et al., 2005; Hannibal et al., 2011; Harmar et al., 2004) . Since our studies demonstrate that hypothalamic VIP expression is reduced in Npy6r-deficient mice, it is possible that the impaired circadian rhythm observed in our Npy6r À/À mice, as evidenced by blunted daily fluctuations in serum corticosterone levels and reduced light-phase feeding, may be due to impaired VIP signaling, and therefore could contribute to the development of metabolic abnormalities in these mice.
In addition to regulating circadian rhythm, VIP is an important regulator of the GH axis. VIP is known to stimulate GH release in rats in vivo (Bluet-Pajot et al., 1987) , in cultured bovine adenohypophysial cells (Soliman et al., 1995) , and in perifused bovine adenohypophysis (Hashizume and Kanematsu, 1990) . Moreover, loss of VIP or VPAC2 in mice leads to reduced growth in association with reduced circulating IGF-1 levels (Asnicar et al., 2002; Niewiadomski et al., 2008) . Indeed, we demonstrate that blockade of VPAC abolishes the Npy6r-mediated alteration of circulating IGF-1 levels. This finding, combined with our observations of reduced SCN Vip mRNA expression and reduced GH/IGF-1 axis activity in our Npy6r À/À mice, suggests that the reduced lean mass and late onset obesity observed in the absence of Npy6r signaling are due to perturbations in normal VIP regulation of the GH/IGF-1 axis. Consistent with known effects of reduced circulating IGF-1 levels in inducing obesity (Rosen et al., 2004) , our data suggest that the lower circulating IGF-1 levels could account for the decreased lean mass and the increased relative adiposity in Npy6r À/À mice. Thus, impairment in function of the GH/IGF-1 axis, as well as impaired circadian rhythmicity resulting from defects in VIP neuronal signaling pathways in the SCN, could have contributed to the reduction in lean body mass and the development of lateonset obesity in Npy6r À/À mice.
In this study, PP was found to be the only high-affinity ligand that can trigger significant elevation of Fos expression in the SCN in WT compared to Npy6r À/À mice. PP is released from pancreatic F cells in response to stimuli such as food intake and hypoglycemia, mainly by vagal muscarinic activation (Havel et al., 1993) . Previously it was thought to be a ligand only for the Ppyr1, triggering responses in the brain stem and ARC to inhibit food intake and enhance digestive events such as gastric secretion, motility, and emptying by subsequent activation of vagal cholinergic pathways (McTigue et al., 1997) . Lack (D and E) Fasted serum IGF-1 and hypothalamic Ghrh mRNA expression were determined in chow-fed Npy6r À/À and WT mice. (F and G) Serum corticosterone levels were assessed at intervals of 6 hr or under fasted condition in Npy6r À/À mice and WT controls. (H and I) Light-and dark-phase food intake was measured for 6 consecutive days in 16-and 23-week-old Npy6r À/À and WT mice. (J and K) Npy6r À/À and WT mice were injected with either saline or PP, and Ghrh mRNA levels in ARC were assessed. (L) Npy6r À/À and WT mice were injected with either saline, PP, or PP and VIP receptor antagonist. Subsequently, serum IGF-1 levels were determined by using IGF-1 ELISA kit. Data are means ±SEM of four to eight mice per group. See also Figure S7 .
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Cell Metabolism 19, 58-72, January 7, 2014 Further evidence supporting the notion of a PP-controlled GH/IGF-1 axis comes from experiments in which we injected PP via the i.c.v. route and measured the consequences on Ghrh mRNA expression in WT compared to Npy6r −/− mice. While i.c.v. administration of PP to WT mice led to a significant increase in Ghrh mRNA levels in the ARC, this PP-dependent effect was absent in Npy6r −/− mice ( Figures 7J and 7K ). Together with our findings of SCNspecific Npy6r expression, colocalization of Npy6r with VIP in the SCN, reduced expression of Vip mRNA in the SCN of Npy6r −/− mice, and PP-induced Fos activation in the SCN, these data indicate that alterations in GH/IGF-1 axis activity in Npy6r −/− mice are a direct consequence of the lack of PP-induced activation of Npy6r in the SCN, possibly via VIP.
Finally, to demonstrate that alterations in downstream VIP signaling are linked to the observed changes in energy homeostasis such as the reduction of IGF-1 levels, we delivered VIP(6-28), a VPAC receptors antagonist, via the i.c.v. route to WT and Npy6r −/− mice, followed 5 min later by i.p. administration of PP. Analysis of serum samples collected 30 min following PP injection revealed that blockade of VPAC receptors in WT mice completely prevented the PP-induced increase in serum IGF-1 in WT mice ( Figure 7L ). Furthermore, the effect of PP to raise serum IGF-1 was totally absent in Npy6r −/− mice ( Figure 7L ), clearly demonstrating involvement of Npy6r signaling via VIP in controlling the growth hormone axis.
Discussion
In this study, we demonstrate that Npy6r signaling in the SCN is critical in the regulation of energy homeostasis. Our results show that body weight, body composition, metabolic rate, and activity of the hypothalamo-pituitary-somatotrophic axis are significantly influenced by Npy6r signaling in mice, since lack of Npy6r leads to reduced lean mass and increased energy expenditure that are accompanied by significant improvements in glucose homeostasis and reduced hypothalamic Ghrh mRNA expression and circulating IGF-1 levels. Interestingly, Npy6r-deficient mice develop late-onset obesity, and this is further exacerbated when mice are fed a high-fat diet. Additionally, we demonstrate that PP is an endogenous high-affinity ligand for Npy6r in mice, since exogenous administration of PP, but not PYY or PYY3-36, activated Npy6r-expressing neurons in the SCN, and this effect was absent in Npy6r-deficient mice. The mechanism by which Npy6r mediates its effects on the GH axis and energy homeostasis is most likely through alterations in VIP signaling in the hypothalamus. This is demonstrated by the strong overlap in expression of Vip and Npy6r within the SCN, the brain region to which the Npy6r is confined, and the significant reduction in Vip expression in this nucleus in the absence of Npy6r signaling. Moreover, the fact that i.p. PP injection increases energy expenditure and decreases food intake, hypothalamic Ghrh mRNA expression, and circulating IGF-1 levels in WT but not in Npy6r −/− mice, and that the effect on IGF-1 is blocked by prior administration of a VPAC receptors antagonist, strongly supports this stand.
It has been documented that the SCN contains the master circadian clock in mammals; it generates distinct temporal changes in biological processes such as core body temperature and hormone secretion (Huang et al., 2011) . Disruptions in circadian rhythm, whether by genetic or environmental influences, can result in metabolic dysfunction (Huang et al., 2011) . For instance, mutation of either of two key regulators of the circadian cycle, circadian locomotor output cycles kaput (CLOCK) or brain and muscle aryl hydrocarbon receptor nuclear translocator (ARNT)-like 1 (BMAL1), not only disrupt normal circadian rhythm, manifesting in loss of normal daily hormonal and feeding patterns, but also predispose mice to metabolic diseases (Marcheva et al., 2010 , Rudic et al., 2004 and Turek et al., 2005 . VIP is a critical regulator of circadian rhythm in the SCN, with deletion of VIP or its receptor, VPAC2, leading to loss of circadian rhythmicity and synchrony in SCN neurons (Aton et al., 2005 , Hannibal et al., 2011 and Harmar et al., 2004 . Since our studies demonstrate that hypothalamic VIP expression is reduced in Npy6r-deficient mice, it is possible that the impaired circadian rhythm observed in our Npy6r −/− mice, as evidenced by blunted daily fluctuations in serum corticosterone levels and reduced light-phase feeding, may be due to impaired VIP signaling, and therefore could contribute to the development of metabolic abnormalities in these mice.
In addition to regulating circadian rhythm, VIP is an important regulator of the GH axis. VIP is known to stimulate GH release in rats in vivo (Bluet-Pajot et al., 1987) , in cultured bovine adenohypophysial cells (Soliman et al., 1995) , and in perifused bovine adenohypophysis (Hashizume and Kanematsu, 1990) . Moreover, loss of VIP or VPAC2 in mice leads to reduced growth in association with reduced circulating IGF-1 levels (Asnicar et al., 2002 and Niewiadomski et al., 2008) . Indeed, we demonstrate that blockade of VPAC abolishes the Npy6r-mediated alteration of circulating IGF-1 levels. This finding, combined with our observations of reduced SCN Vip mRNA expression and reduced GH/IGF-1 axis activity in our Npy6r −/− mice, suggests that the reduced lean mass and late onset obesity observed in the absence of Npy6r signaling are due to perturbations in normal VIP regulation of the GH/IGF-1 axis. Consistent with known effects of reduced circulating IGF-1 levels in inducing obesity ( Rosen et al., 2004) , our data suggest that the lower circulating IGF-1 levels could account for the decreased lean mass and the increased relative adiposity in Npy6r −/− mice. Thus, impairment in function of the GH/IGF-1 axis, as well as impaired circadian rhythmicity resulting from defects in VIP neuronal signaling pathways in the SCN, could have contributed to the reduction in lean body mass and the development of late-onset obesity in Npy6r −/− mice. In this study, PP was found to be the only high-affinity ligand that can trigger significant elevation of Fos expression in the SCN in WT compared to Npy6r −/− mice. PP is released from pancreatic F cells in response to stimuli such as food intake and hypoglycemia, mainly by vagal muscarinic activation (Havel et al., 1993) . Previously it was thought to be a ligand only for the Ppyr1, triggering responses in the brain stem and ARC to inhibit food intake ) and enhance digestive events such as gastric secretion, motility, and emptying by subsequent activation of vagal cholinergic pathways (McTigue et al., 1997) . Lack of Ppyr1 signaling in mice leads to reduced body weight and fat mass on a lean background, and attenuation of certain aspects of the obesity syndrome and enhanced fertility on a background of leptin deficiency ( Sainsbury et al., 2002b and Zhang et al., 2010) . However, satiety regulation of PP via Ppyr1 signaling seems to be mainly confined to the ARC in the hypothalamus, particularly to neurons that coexpress alpha melanocyte stimulating hormone (α-MSH) . It is possible that the reduced body weight or attenuated obesity syndrome of Ppyr1 −/− mice was mediated by the high circulating PP concentrations seen in these mice, acting on other Y receptors besides Ppyr1, such as the herein-identified Npy6r. In support of this, PP transgenic mice, which have a 20-fold increase in plasma PP levels, have a similar metabolic phenotype to Ppyr1 −/− mice (Ueno et al., 1999) . Our current data extend these findings to suggest that the late-onset obesity phenotype of our Npy6r −/− mice could be mediated by lack of action of PP on Npy6r in the SCN.
In summary, our study demonstrates that Npy6r is a critical regulator of energy homeostasis and body composition, with germline deletion of Npy6r leading to reduced body weight, inhibition of lean body mass, and an age-dependent increase in adiposity that is exacerbated by high-fat feeding, with these effects likely mediated via the lack of Npy6r signaling in the SCN to influence the VIP-GH/IGF-1 axis. Future studies in mice into the function and possible clinical utility of Y receptors and their ligands as drug targets must therefore take into account this new knowledge that Npy6r plays an important role in the regulation of energy homeostasis.
Experimental Procedures
Animals
All animal care and experiments were approved by the Garvan/St. Vincent's Animal Ethics Committee. Npy6r −/− mice were generated and genotyped as described in Supplemental Experimental Procedures. Male mice on a mixed C57BL/6-129SvJ background were used for all experiments, except where noted. Mice were housed under a controlled temperature of 22°C and a 12 hr light cycle (lights on from 07:00 to 19:00 hr) with ad libitum access to water and a standard chow diet (6% calories from fat, 21% calories from protein, 71% calories from carbohydrate, 2.6 kcal/g, Gordon's Specialty Stock Feeds, Australia) or fed a HFD (43% kilojoules from fat, 17% kilojoules from protein, 40% kilojoules from carbohydrate, 4.8 kcal/g, Specialty Feeds, Australia) for 16 weeks starting from 7-8 weeks of age.
RNA Extraction and Quantitative Real-Time PCR
Hypothalami were dissected and immediately frozen in liquid N 2 , and RNA was extracted using Trizol Reagent (Sigma, St. Louis, MO) and processed for quantitative real-time PCR with the Light-Cycler 480 Real-Time PCR system (Roche, Switzerland) as described in the Supplemental Experimental Procedures.
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Metabolic Measurements and Body Composition
Weekly body weight was determined from 6 weeks of age onward, unless otherwise stated. Food intake and fecal output were examined in chow-and high-fat-fed mice under normal and fasting states as described in the Supplemental Experimental Procedures. Whole-body lean and fat masses were determined by DXA (Lunar Piximus II mouse densitometer; GE Healthcare, UK) as previously described (Baldock et al., 2009 and Zhang et al., 2010) . VO 2 , energy expenditure, RER, and physical activity were assessed using an indirect calorimeter (Oxymax series; Columbus Instruments, Columbus, OH) as described in the Supplemental Experimental Procedures.
Glucose Tolerance Tests and Serum Assays
Mice were fasted for 16-18 hr and i.p. administered with glucose (1 mg/kg body weight). Blood glucose levels were assessed at 0, 15, 30, 60, and 90 min after glucose administration using an Accu-chek Go glucometer (Roche, Dee Why, Australia). Serum was collected and stored for subsequent insulin assay. Serum insulin, testosterone, IGF-1, VIP, and corticosterone levels were measured in accordance with the manufacturers' specifications as described in the Supplemental Experimental Procedures.
Oil Red O and β-Galactosidase Staining
Frozen livers sections (6 µm) were cut on a cryostat, mounted on slides, and processed for oil red O staining as described in the Supplemental Experimental Procedures. Coronal brain and peripheral tissue frozen sections (25 µm) were mounted on slides and processed for βgalactosidase histochemistry as described in the Supplemental Experimental Procedures.
Immunohistochemistry
Animals were anesthetized, and the brains were perfused with saline and then 4% paraformaldehyde (PFA). Brains were postfixed in 4% PFA, then placed in 30% sucrose overnight and cut at 35 µm on a cryostat. Subsequently, immunohistochemistry was performed using antibodies against Fos, p-ERK, VIP, or AVP. Fos expression was visualized in brain sections containing the SCN (Bregma −0.34 mm through to −0.70 mm) (Franklin and Paxinos, 1997) with a light microscope (Leica, Heerbrugg, Switzerland). The number of Fospositive neurons within a constant and defined frame was counted using ImageJ64 software (National Institutes of Health).
In Situ Hybridization and Colocalization Study
Coronal brain sections (30 µm) were cut on a cryostat and mounted on slides. Matching sections from the same coronal brain level from different groups of mice were examined together using radiolabeled DNA oligonucleotides complementary to mouse Vip and Ghrh. Sequence of probes and details of the in situ hydridization methodology can be found in the Supplemental Experimental Procedures. For colocalization of Npy6r and Vip study, coronal brain section were first processed for β-gal staining, then followed by in situ hydridization as described in the Supplemental Experimental Procedures. Slides were visualized and imaged with a light microscope (Leica, Heerbrugg, Switzerland).
Stereotaxic Brain Delivery of Peptides
Adult mice were anaesthetized and placed on a Kopf stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA). A total of 1 µl PP or 1.5 µl VPAC2 antagonist (2 µg/ul) was injected into the lateral ventricle at a rate of 0.1 µL/min using a 10 µl Hamilton syringe attached to Micro4 Micro Syringe Pump Controller (World Precision Instruments Inc., Sarasota). The injection coordinates were (from bregma) as follows: anteroposterior, -0.34 mm; mediolateral, ±1.00 mm; and dorsoventral, -2.5 mm (Franklin and Paxinos, 1997) . Animals were kept on a heating pad during surgery.
Statistical Analyses
All data are expressed as mean ±SEM. A two-tailed Student's t test was used to test the difference between two groups of mice. Differences among groups of mice were assessed by two-way ANOVA or repeated-measures ANOVA. Bonferroni post hoc tests were performed to identify differences among means. Statistical analyses were assessed using Prism software (GraphPad Software, Inc, LaJolla). Differences were regarded as statistically significant if p < 0.05.
